Clinical Trial Update: A Phase 1/2 Study of Ramucirumab Plus Nivolumab in Participants With Gastric or GEJ Cancer [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 study updates on ramucirumab plus nivolumab in gastric and GEJ cancer completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Cancer
• Gastroesophageal Junction Cancer

Drugs mentioned

• Ramucirumab (ramucirumab)
• nivolumab (nivolumab)

Snippet

Sponsor: National Cancer Center, Japan | Conditions: Gastric Cancer, Gastroesophageal Junction Region (GEJ) Cancer | Phase 1, Phase 2 | Status: COMPLETED